<p>Johnson & Johnson contractor Emergent Biosolutions Inc plans to resume Covid-19 vaccine production at its Baltimore plant after getting approval from the US Food and Drug Administration (FDA), the <em>Wall Street Journal</em> <a href="https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=latest_headlines" target="_blank">reported</a> late on Wednesday, citing a statement from the company and a FDA letter.</p>.<p>Production of J&J's Covid-19 vaccine at the Baltimore site was halted by US authorities in April following a discovery that ingredients from AstraZeneca's Covid-19 vaccine, also being produced at the plant at that time, contaminated a batch of J&J's vaccines.</p>.<p>J&J, Emergent and the FDA did not immediately respond to Reuters requests for comment</p>
<p>Johnson & Johnson contractor Emergent Biosolutions Inc plans to resume Covid-19 vaccine production at its Baltimore plant after getting approval from the US Food and Drug Administration (FDA), the <em>Wall Street Journal</em> <a href="https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=latest_headlines" target="_blank">reported</a> late on Wednesday, citing a statement from the company and a FDA letter.</p>.<p>Production of J&J's Covid-19 vaccine at the Baltimore site was halted by US authorities in April following a discovery that ingredients from AstraZeneca's Covid-19 vaccine, also being produced at the plant at that time, contaminated a batch of J&J's vaccines.</p>.<p>J&J, Emergent and the FDA did not immediately respond to Reuters requests for comment</p>